Orally active hydrogen sulfide-releasing cyclooxygenase inhibitor and a derivative of Naproxen (significantly reduced exudate leukocyte and PGE2 levels at 30 µmol/kg oral administration). ATB-346 exhibits anti-inflammatory properties similar to naproxen.In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen but with substantially reduced gastrointestinal toxicity (100-fold safer than naproxen).

KEYWORDS: ATB 346 | supplier | COX inhibitor; H2S-releasing compound | ATB346 | CAS [1226895-20-0] | Fatty acid (Arachidonic acid) | COX | Inhibitor | cyclooxygenase | Naproxen | anti-inflammatory | leukocyte infiltration